Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Myriad Builds Case For Personalized Prescribing Of Rheumatoid Arthritis Drugs

This article was originally published in The Pink Sheet Daily

Executive Summary

Data presented at the American College of Rheumatology meeting show that not everybody needs a biologic, and that biomarker testing could enable more cost-effective use, says Myriad subsidiary Crescendo.

Advertisement

Related Content

Biomarkers Improve Odds Of Approval, BIO Study Finds
Making The Most Of A Maturing Myriad Genetics

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register